Historic Approval for MASH, CAR-Ts in the Spotlight

The Weekly BioSpace News Podcast

Phew, what a week!

One of the most anticipated FDA decisions of the year dropped last week when the regulator ⁠approved Madrigal’s Rezdiffra⁠ as the first therapy for MASH (⁠formerly known as NASH⁠).  

Then on Friday, BioSpace kept a close eye on an ⁠advisory committee discussing⁠ J&J’s Carvykti and BMS’s Abecma, two CAR-T therapies seeking label expansions as earlier lines of treatment in multiple myeloma despite the risk of early death.

Also discussed: BIO’s decision from last week to ⁠cut ties with⁠ the China-based biotech WuXi AppTec. 

Greg Slabodkin is the News Editor at BioSpace. You can reach him at greg.slabodkin@biospace.com. Follow him on LinkedIn.     

Heather McKenzie is a senior editor at BioSpace. You can reach her at heather.mckenzie@biospace.com. Follow her on LinkedIn.

Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.

> Listen on Spotify

> Listen on Apple Podcasts

> Listen on Amazon Music

> Listen on iHeart

Back to news